Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference
Journal of Viral Hepatitis, Volume 18, No. SUPPL. 1, Year 2011
Notification
URL copied to clipboard!
Description
Worldwide, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) cause, respectively, 600 000 and 350 000 deaths each year. Viral hepatitis is the leading cause of cirrhosis and liver cancer, which in turn ranks as the third cause of cancer death worldwide. Within the WHO European region, approximately 14 million people are chronically infected with HBV, and nine million people are chronically infected with HCV. Lack of reliable epidemiological data on HBV and HCV is one of the biggest hurdles to advancing policy. Risk groups such as migrants and injecting drug users (IDU) tend to be under-represented in existing prevalence studies; thus, targeted surveillance is urgently needed to correctly estimate the burden of HBV and HCV. The most effective means of prevention against HBV is vaccination, and most European Union (EU) countries have universal vaccination programmes. For both HBV and HCV, screening of individuals who present a high risk of contracting the virus is critical given the asymptomatic, and thereby silent, nature of disease. Screening of migrants and IDUs has been shown to be effective and potentially cost-effective. There have been significant advances in the treatment of HCV and HBV in recent years, but health care professionals remain poorly aware of treatment options. Greater professional training is needed on the management of hepatitis including the treatment of liver cancer to encourage adherence to guidelines and offer patients the best possible outcomes. Viral hepatitis knows no borders. EU Member States, guided by the EU, need to work in a concerted manner to implement lasting, effective policies and programmes and make tackling viral hepatitis a public health priority. © 2011 Blackwell Publishing Ltd.
Authors & Co-Authors
Hatzakis, Angelos E.
Greece, Athens
School of Medicine
Wait, Suzanne H.
United Kingdom, London
Shw Health Ltd
Bruix, Jordi
Spain, Barcelona
Universitat de Barcelona
Butí, María Asunción
Spain, Barcelona
Hospital Universitari Vall D'hebron
Carballo, Manuel
Switzerland, Geneve
Intl. Ctr. for Migration and Health
Cavaleri, Marco
Netherlands, Amsterdam
European Medicines Agency
Colombo, Massimo Giuseppe
Italy, Milan
Università Degli Studi Di Milano
Delarocque-Astagneau, Elisabeth
France, Saint-maurice
Institut de Veille Sanitaire
Dusheiko, Geoffrey M.
United Kingdom, London
The Royal Free Hospital
Esmat, Gamal
Egypt, Cairo
Faculty of Medicine
Esteban, Rafael
Spain, Barcelona
Hospital Universitari Vall D'hebron
Goldberg, David J.
United Kingdom, Glasgow
Health Protection Scotland
Gore, Charles
United Kingdom, London
World Hepatitis Alliance
Lok, Anna Suk Fong
United States, Ann Arbor
Michigan Medicine
Manns, Michael Peter
Germany, Hannover
Hannover Medical School
Marcellin, Patrick M.
France, Paris
Centre de Recherche Biomédicale Bichat-beaujon
Papatheodoridis, George V.
Greece, Athens
School of Medicine
Peterle, A.
Belgium, Brussels
European Parliament
Prati, Daniele
Italy, Milan
Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico
Piorkowsky, Nadine Y.
Belgium, Brussels / Bruxelles
European Liver Patients Association
Rizzetto, Mario
Italy, Turin
Università Degli Studi Di Torino
Roudot-Thoraval, Françoise
France, Saint-maurice
Institut de Veille Sanitaire
Soriano, Vicente Vicente
Spain, Madrid
Hospital Universitario la Paz
Thomas, Howard C.
United Kingdom, London
Imperial College London
Thursz, Mark R.
United Kingdom, London
Imperial College London
Valla, Dominique Charles
France, Clichy
Hôpital Beaujon
Van-Damme, Pierre A.
Belgium, Wilrijk
Faculteit Geneeskunde en Gezondheidswetenschappen
Veldhuijzen, Irene Karen
Netherlands, Rotterdam
Public Health Service of the Rotterdam Region
Wedemeyer, Heiner
Germany, Hannover
Gottfried Wilhelm Leibniz Universität Hannover
Wiessing, Lucas G.
Portugal, Lisbon
European Monitoring Centre for Drugs and Drug Addiction
Zanetti, Alessandro Remo
Italy, Milan
Università Degli Studi Di Milano
Janssen, Harry L.A.
Netherlands, Rotterdam
Erasmus Mc
Statistics
Citations: 247
Authors: 32
Affiliations: 27
Identifiers
Doi:
10.1111/j.1365-2893.2011.01499.x
ISSN:
13520504
e-ISSN:
13652893
Research Areas
Cancer
Health System And Policy
Infectious Diseases
Study Design
Cross Sectional Study